Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
15 déc. 2022 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
09 nov. 2022 16h05 HE
|
Cyclacel
- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and...
Cyclacel Hosting Research & Development Day
24 oct. 2022 09h15 HE
|
Cyclacel
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31st @ 10 am ET- ...
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
21 sept. 2022 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
03 août 2022 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
11 mai 2022 16h05 HE
|
Cyclacel
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of...
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
04 mai 2022 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
28 mars 2022 16h05 HE
|
Cyclacel
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 – -Cash Runway to Mid 2023- -Conference Call Scheduled for March 28, 2022, at...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
22 mars 2022 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
09 mars 2022 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...